Evidence map›Paper›PMID 27436846›Full record

ArticleCirculation research2016

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Svetlana A Didichenko, Alexei V Navdaev, Alexandre M O Cukier, Andreas Gille, Patrick Schuetz, Martin O Spycher, Patrice Thérond, M John Chapman, Anatol Kontush, Samuel D Wright

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 102 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Associations of plasma HDL subclasses with incident dementia risk in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Svetlana A DidichenkoFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Alexei V NavdaevFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Alexandre M O CukierFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Andreas GilleFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Patrick SchuetzFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Martin O SpycherFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Patrice ThérondFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
M John ChapmanFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Anatol KontushFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.).
Samuel D WrightFrom the CSL Behring AG, Berne, Switzerland (S.A.D., A.V.N., P.S., M.O.S.); National Institute for Health and Medical Research (INSERM), UMR-ICAN 1166, Paris, France (A.M.O.C., M.J.C., A.K.); University of Pierre and Marie Curie - Paris 6, France (A.M.O.C., M.J.C., A.K.); Pitié - Salpétrière University Hospital; ICAN, Paris, France (A.M.O.C., M.J.C., A.K.); CSL Limited, Parkville, VIC, Australia (A.G.); AP-HP, HUPS Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (P.T.); and CSL Behring, King of Prussia, PA (S.D.W.). samuel.wright@cslbehring.com.
Fondation pour l’innovation en Cadiométabolisme et Nutrition · FRSorbonne Université · FRCSL (Australia) · AUCSL (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCSL112, human apolipoprotein A-I (apoA-I) reconstituted with phosphatidylcholine, is known to cause a dramatic rise in small high-density lipoprotein (HDL).

objectiveTo explore the mechanisms by which the formation of small HDL particles is induced by CSL112. METHODS AND

resultsInfusion of CSL112 into humans caused elevation of 2 small diameter HDL fractions and 1 large diameter fraction. Ex vivo studies showed that this remodeling does not depend on lipid transfer proteins or lipases. Rather, interaction of CSL112 with purified HDL spontaneously gave rise to 3 HDL species: a large, spherical species composed of apoA-I from native HDL and CSL112; a small, disc-shaped species composed of apoA-I from CSL112, but smaller because of the loss of phospholipids; and the smallest species, lipid-poor apoA-I composed of apoA-I from HDL and CSL112. Time-course studies suggest that remodeling occurs by an initial fusion of CSL112 with HDL and subsequent fission leading to the smaller forms. Functional studies showed that ATP-binding cassette transporter 1-dependent cholesterol efflux and anti-inflammatory effects in whole blood were carried by the 2 small species with little activity in the large species. In contrast, the ability to inactivate lipid hydroperoxides in oxidized low-density lipoprotein was carried predominantly by the 2 largest species and was low in lipid-poor apoA-I.

conclusionsWe have described a mechanism for the formation of small, highly functional HDL species involving spontaneous fusion of discoidal HDL with spherical HDL and subsequent fission. Similar remodeling is likely to occur during the life cycle of apoA-I in vivo.

Indexed as

AnimalsAnti-Inflammatory AgentsAntioxidantsCell LineCholesterolHumansInfusions, IntravenousLipoproteins, HDLMiceMice, Inbred C57BLMice, KnockoutOxidative StressAnti-Inflammatory AgentsAntioxidantsCholesterolCSL112Lipoproteins, HDLantioxidantapolipoprotein A-Icholesterolhigh-density lipoproteinsinflammation

Identifiers

PMID27436846
PMCPMC5006797
OpenAlexW2498364729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.